title: [Osteoporosis: basics and pitfalls].
abstract: Osteoporosis belongs to the ten most common diseases. There is no doubt about the importance of primary prophylaxis. Regarding postmenopausal women the following subjects will be discussed: How can the fracture risk be evaluated? What kind of pharmacotherapy is available? An osteodensitometry will be performed if risk factors are present. Most of the laboratory testing can be done in a primary care unit to exclude secondary forms of osteoporosis. Guidelines concerning the decision to start a therapy are based on the individual risk profile and on the osteodensitometric score. The pharmacotherapy with bisphosphonates, selective estrogen receptor modulators and parathormone will be discussed. Strontiumranelate is a very promising medicine and will soon be available in Switzerland.
authors.affiliation: Medizinische Poliklinik, Universitätsspital Basel. philippe.rafeiner@kssg.ch
authors.forename: P
authors.initials: P
authors.lastname: Rafeiner
mesh_terms: D015502:Absorptiometry, Photon; D000368:Aged; D004164:Diphosphonates / Q000009:adverse effects / Q000627:therapeutic use; D020847:Estrogen Receptor Modulators / Q000009:adverse effects / Q000627:therapeutic use; D005260:Female; D005598:Fractures, Spontaneous / Q000517:prevention & control; D006801:Humans; D008875:Middle Aged; D009942:Organometallic Compounds / Q000009:adverse effects / Q000627:therapeutic use; D015663:Osteoporosis, Postmenopausal / Q000175:diagnosis* / Q000188:drug therapy; D010281:Parathyroid Hormone / Q000009:adverse effects / Q000627:therapeutic use; D017410:Practice Guidelines as Topic; D011320:Primary Health Care; D012307:Risk Factors; D013876:Thiophenes / Q000009:adverse effects / Q000627:therapeutic use
chemical_list: D004164:Diphosphonates; D020847:Estrogen Receptor Modulators; D009942:Organometallic Compounds; D010281:Parathyroid Hormone; D013876:Thiophenes; C081587:strontium ranelate